Nevirapine induced Stevens Johnson Syndrome
A 56-year-old male patient presented with a complaint of lesions all over the body with a burning sensation for 4 days. He was on an ART regimen, containing zidovudine, lamivudine, and efavirenz combination for 4 years. But patient accidentally started nevirapine and after 10 days he developed maculopapular lesions which were diagnosed as SJS syndrome. There was a history of rash with nevirapine when ART was started initially in 2012. This incident of an adverse event could be assigned a term "probable" according to the WHO-UMC scale for causality assessment as the re-challenge was found positive. Severe and life-threatening SJS is more common with nevirapine than with other NNRTIs. Physicians and patients must be aware of this adverse effect on early diagnosis and treatment.
Alsaad KO, Ghazarian D. My approach to superficial inflammatory dermatoses. Journal of Clinical Pathology, 2005; 58(12):1233-1241.
Budamakuntla L, Loganathan E, Suryanarayan S, Abhishek K, Sarvajnamurthy S. Nevirapine induced toxic epidermal necrolysis and non-Hodgkin lymphoma in a human immunodeficiency virus-positive patient. Indian Dermatology Online Journal, 2014;5(2):179- 181.
Knobel H, Guelar A, Montero M, et al. Risk of side effects associated with the use of nevirapine in treatment- naive patients, with respect to gender and CD4 cell count. HIV Medicine, 2008; 9(1):14-18
McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long- versus short- course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Safety, 2009;32(2):147-158.
Namayanja GK, Nankya JM, Byamugisha JK, et al. Stevens - Johnson syndrome due to nevirapine. African health sciences, 2005;5(4):338-340.
Pau AK, and George JM. Antiretroviral therapy: current drugs. Infectious disease clinics of North America, 2014; 28(3): 371-402.
Philip MM, Kesavan KP, Prakash J. Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide. Journal of Pharmacovigilance and Drug Research, 2020; 1(1): 19- 21.
Rapsang AG, Shyam DC. Scoring systems in the intensive care unit: A compendium. Indian journal of critical care medicine, 2014;18(4):220-228
Reddy RB, Shekar PC, Chandra KL, Aravind R. Oral lesions associated with Nevirapine-induced Stevens- Johnson syndrome and toxic epidermal necrolysis: A report of 10 cases. Journal of oral and maxillofacial pathology, 2013;17(3):431-435.
Sinha S, Raghunandan P, Chandrashekhar R, et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases, 2013;13:482.
Su SC and Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel). 2014;6(1):194-210.
Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of the International AIDS Society, 2013;16(1):1-14.
Copyright (c) 2020 Himani Prajapati, Neetu Bala, Dinesh Kansal
This work is licensed under a Creative Commons Attribution 4.0 International License.